Benjamin Dowsing

Benjamin Dowsing

Auto-generated profile, based on publicly available information

Benjamin Dowsing

Institute of Cardiovascular Science, University College London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in BMJ Open
Verified
Journal Article
Open access
BDBenjamin Dowsing
Benjamin Dowsing
HDHakim-Moulay Dehbi
Hakim-Moulay Dehbi
RCRobin Chung
Robin Chung
JPJoanna Pedra
Joanna Pedra
OWOrla Worn
Orla Worn
CMCharlotte H Manisty
Charlotte H Manisty
Introduction: A quarter of breast cancers show human epidermal growth factor-2 (HER2) overexpression, where targeted therapy dramatically improves survival. However, cancer therapy-related cardiac dysfunction (CTRCD) occurs in up to 15% of patients. With the interruption of HER2 therapy, if necessary, and the initiation of heart failure therapy (HFT), HER2 CTRCD recovers in over 80% of cases. The need to continue HFT in ‘recovered’ HER2 CTRCD following completion of HER2 therapy is unclear and there are potential significant impacts on patient’s quality of life (QoL). The Randomised Controlled Trial for the Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction (HER-SAFE) aims to evaluate whether HFT can be safely withdrawn in non-high cardiovascular (CV) risk patients with ‘recovered’ HER2 CTRCD. Methods and analysis: This is a multicentre, open-label randomised controlled trial investigating whether withdrawal of HFT is non-inferior to continuation in non-high CV risk, breast cancer survivors with recovered HER2 CTRCD after cancer treatment completion. The primary endpoint is the incidence of guideline-defined cardiac dysfunction or clinical heart failure. Secondary endpoints include changes in cardiac blood biomarkers, cardiovascular magnetic resonance (CMR)-derived strain and tissue mapping and heart failure symptom questionnaires. The study will recruit 90 participants who will undergo serial clinical assessment over 12 months with advanced cardiovascular imaging (CMR scans with automated analysis at baseline, 6 and 12 months), cardiac biomarker measurement (six time points over 12 months), plus complete heart failure QoL and medication disutility questionnaires. This is the first multicentre study to address this significant clinical issue. Ethics and dissemination: This study was approved by the research ethics committee (London—London Bridge, 23/LO/0152). The results will be disseminated in peer-reviewed scientific journals. Trial registration number: NCT05880160 .

30 August 2026 in European Heart Journal
Verified
Journal Article
Open access
BDBenjamin Dowsing
Benjamin Dowsing
HDHakim-Moulay Dehbi
Hakim-Moulay Dehbi
MAMaria Sol Andres
Maria Sol Andres
RCRobin Chung
Robin Chung
AQAhmed Qashou
Ahmed Qashou
CMCharlotte H Manisty
Charlotte H Manisty
Background and Aims: Heart failure therapy (HFT) is routinely continued in breast cancer survivors after recovery from anti-HER2 cancer therapy-related cardiac dysfunction (CTRCD), despite limited evidence. HER-SAFE is the first randomized trial to assess HFT withdrawal in this population. Methods: In this open-label, multicentre, randomized controlled, non-inferiority trial, breast cancer survivors with recovered anti-HER2 CTRCD (asymptomatic, left ventricular ejection fraction [LVEF] ≥50%, normalized biomarkers) were randomized to HFT withdrawal or continuation. Antecedent CTRCD was mild (relative global longitudinal strain [GLS] decline >15%, LVEF ≥50%), moderate (LVEF fall >10% to <50%), or severe (LVEF <40%). The primary endpoint was a moderate or severe CTRCD event over 12 months analysed by intention to treat; secondary endpoints included serial cardiac function, biomarkers, and quality of life. Results: Between July 2023 and June 2025, 90 patients were randomized (all female; median age 50 years [IQR 43–59]; median 17.3 months [IQR 7.7–33.2] since CTRCD recovery; HFT predominantly renin–angiotensin system inhibitors [98%] and beta-blockers [88%])—46 randomized to HFT withdrawal (1 lost to follow-up) and 44 to continuation. The primary endpoint occurred in 1 of 45 with withdrawal (moderate asymptomatic CTRCD) vs 0 of 44 with continuation (between-group difference 2.2pp; 90% CI upper limit 9.4pp - below the pre-specified 10pp non-inferiority margin). No cardiovascular deaths, heart failure hospitalizations or symptomatic CTRCD occurred. Cardiac magnetic resonance imaging-derived LVEF remained stable in both arms at 12 months (between-group difference −0.8% [−2.0 to +0.4], P = .21). Conclusions: Among breast cancer survivors with recovered anti-HER2 CTRCD, HFT withdrawal was not associated with symptomatic events or significant between-group difference in LVEF at 12-months.

2 July 2026 in European Heart Journal - Imaging Methods and Practice
Verified
Journal Article
Open access
BDBenjamin Dowsing
Benjamin Dowsing
KMKatia Menacho
Katia Menacho
VCVerónica Culotta
Verónica Culotta
BMBenjamin Meredith
Benjamin Meredith
BUBeth Unsworth
Beth Unsworth
CMCharlotte H Manisty
Charlotte H Manisty
Aims: Serial imaging demands precision—particularly for cardiotoxicity screening where small changes gatekeep major decisions. Automated measurement using artificial intelligence (AI)-based techniques should reduce variability and increase confidence for detection of true change. We directly compared the precision of fully automated AI vs. expert manual analysis of left ventricular function by echocardiography. Methods and results: Consecutive cancer patients referred for cardiotoxicity monitoring underwent same-day repeat 2D echocardiography [n = 60, 83% female, mean left ventricular ejection fraction (LVEF) 57 ± 7%], with 3D acquisition where feasible (n = 45). All 2D images underwent blinded analysis by a fully automated analysis software and four experts. Quantitative 2D LVEF measurement was feasible in 96% scans by both methods. Mean absolute difference (MAD) between repeat scans was significantly lower for AI than experts for both 2D LVEF {3.6% [confidence interval (CI) 2.8–4.4] vs. 6.6% [CI 5.3–7.9], P = 0.011} and global longitudinal strain [1.5% (CI 1.1–1.9) vs. 2.5% (CI 2.0–3.0), P = 0.006]. In participants with 3DE datasets, 3D LVEF MAD was lower than manual 2D LVEF [3.6% (CI 2.8–4.6) vs. 6.4% (CI 5.0–8.0), P = 0.006] but comparable to AI-derived 2D LVEF [3.5% (CI 2.9–4.2), P = 0.4]. In a subset (n = 48) also with same-day cardiovascular magnetic resonance (CMR) studies, AI 2DE analysis demonstrated stronger agreement with CMR than expert 2DE analysis [LVEF MAD 5.0% (CI 4.1–5.9) vs. 7.8% (CI 6.6–9.0) P = 0.006]. Conclusion: In cancer patients at risk of cardiotoxicity, the precision of 2D echocardiographic AI analysis exceeds that of experts, matching that of 3D LVEF assessment. Trial Registration: NCT06817044 Lay summary: Some cancer treatments may weaken the heart. As such, at-risk patients have repeat heart scans (echocardiograms) over the course of their cancer treatment. Doctors monitor these scans over time and watch closely for any change; even a small decline in heart function can trigger a major decision, such as pausing life-saving cancer therapy. It is therefore vital that these measurements are as consistent or ‘precise’ as possible. The problem is that measurements taken by hand can vary widely, and ‘precision’ may be low, even when performed by skilled experts. This makes it hard to know whether a change in heart function across follow-up scans is real or not and whether any action is therefore needed. We tested whether artificial intelligence (AI) software could measure heart function more precisely than experts. Sixty cancer patients each had two echocardiographic heart scans in close succession on the same day. This approach purposefully reduces the impact of other factors (such as differences in the person or equipment performing the heart scan) that might otherwise mean results differ. We then compared how closely the repeat measurements of heart function matched when performed by AI vs. four echocardiography experts. The AI was more precise, giving closer results between the two scans, whilst the experts’ results varied more. In short, AI can measure heart function more precisely than experts in patients with cancer. This could give doctors greater confidence that any change seen on a scan is genuine, helping them make safer, better-informed decisions.

3 August 2026 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
BDBenjamin Dowsing
Benjamin Dowsing

4 June 2021 in Heart
Verified
Conference Paper
Open access
PDF file
BDBenjamin Dowsing
Benjamin Dowsing
ABAnish Bhuva
Anish Bhuva
LCLizette Cash
Lizette Cash
EWEmily Webb
Emily Webb
JMJames Moon
James Moon
CMCharlotte Manisty
Charlotte Manisty
Introduction Patients with cardiac implantable electronic devices (CIEDs) should have access to Magnetic Resonance Imaging (MRI) when needed. Patients are still less likely to be referred and hospitals may not provide a service. A major barrier is reducing the logistical demand required at scale for a safe service. We aimed to quantify the logistical requirements of a high-volume Cardiac Device-MRI service. Methods A single centre retrospective audit of a high-volume Cardiac Device-MRI service in a tertiary cardiac imaging unit in the UK. Six months of consecutive referrals from September 2020 were reviewed for patient and CIED details and barriers met. Referrals were sorted by source, indication, MR-Conditional labelling and referrer specialty. Results 116 MRIs (48% cardiac, 52% non-cardiac) were performed on CIED patients in six months (table 1). 53% were external referrals, 11% inpatient and 25% were suspected malignancy. Referrers were 47% cardiologists and 53% other specialty. Time from referral to scan was 15 days (interquartile range, IQR: 8 – 32). There were no complications.70% of referrals contained complete CIED details and 34% identified the CIED MR labelling. 17% were referred with incorrect MR-Conditional labelling and 8% with incorrect non-MR Conditional labelling. 7 additional days were required to obtain complete CIED details, 10% had delays over 2 weeks (0-145 days). A cardiac physiology department was contacted for 54%, involving 2 departments in 27%. For cancer referrals, obtaining correct details took 1 day longer compared to other referrals and required 2 extra emails to maintain provision within the national time to treatment targets of 62 days. Missing data was similarly present in referrals from Cardiologists and non-Cardiologists (59% versus 61% respectively). The non-Cardiologists recorded more incorrect CIED details (8% vs 0%) (figure 1). External referrals required 17 days (11 – 42), compared to 14 (6 -35) days for internal referrals to obtain CIED information. Missing data was similarly present in external and internal referrals (67% versus 64%), and 35% required 3 or more repeat discussions with referrers after initial referral. Patients with non-MR Conditional CIED took 14 days longer to obtain complete referral details than MR-Conditional CIEDs. Even when referrers were aware of non-MR Conditional labelling, 41% required further discussion between patient and referrer regarding risks and benefits of MRI scanning. Conclusions Both cardiology and non-cardiology referrers of patients with cardiac implantable electronic devices to MRI incorrectly classify MR-Conditional labelling. There is a large logistical burden to maintaining an MRI service for patients with CIEDs and may explain why some patients are not referred for MRI when required. An online referrals platform is under development to streamline this process, and institutional registration is available at www.mrimypacemaker.com. Conflict of Interest Nil

1 October 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
BDB Dowsing
B Dowsing
LCL Cash
L Cash
EWE Webb
E Webb
JMJ C Moon
J C Moon
CMC H Manisty
C H Manisty
ABA N Bhuva
A N Bhuva
Introduction: Patients with cardiac implantable electronic devices (CIEDs) should have access to Magnetic Resonance Imaging (MRI) but are less likely to be referred and hospitals lack provision. A major barrier to service delivery is the administrative demand required to obtain accurate CIED details prior to scheduling. We aimed to understand the administrative requirements of a high-volume Cardiac Device-MRI service to inform the design of an electronic referrals platform that can facilitate workflow. Methods: Single centre retrospective audit of a high-volume Cardiac Device-MRI service in a tertiary unit in the UK. Six months of referrals were reviewed for patient and CIED details and barriers met. Referrals were stratified by source, indication, MR-Conditional labelling and referrer. Results: Administrative barriers were reviewed for 116 patients with CIEDs referred for MRI (48% cardiac, 52% non-cardiac) between September 2020 and March 2021 (Table 1). Referrers were 47% cardiologists and 53% other specialties. Referral to scan time was 15 days (interquartile range, 8–32). There were no scan-related complications. 34% of referrals contained complete CIED details and 30% stated the MR labelling of the CIED. None incorrectly labelled a CIED as MR-Conditional, but 8% incorrectly labelled as non-MR Conditional. 7 additional days were required to obtain complete CIED details where not provided (involving information requests from two device clinics in 27%), 10% had delays over 2 weeks (maximum 145 days). 35% required 3 or more repeat discussions with referrers after initial referral. Obtaining CIED information for external referrals required 17 days (11–42), compared to 14 (6–35) days for internal referrals (p=0.25). Patients with non-MR Conditional CIEDs required on average 14 days longer to obtain complete referral details than patients with MR-Conditional CIEDs. Even when referrers were aware of non-MR Conditional labelling and received information on risk, 41% required further discussion between patient and referrer regarding risks and benefits of MRI scanning. For cancer referrals, obtaining correct details took 1 day longer than other referrals (p=0.074) and required 2 extra emails to maintain provision within the national time-to-treatment target of 62 days. Missing data was similarly present in referrals from Cardiologists and non-Cardiologists (59% versus 61% respectively), but non-Cardiologists recorded more incorrect CIED details (8% vs 0%). Conclusions: Referral for MRI in patients with CIEDs demands significant administrative input to obtain correct device information, leading to delays. These delays are greater for patients with non-MR conditional CIEDs, and data provided is often incorrect or incomplete. This may explain why some patients are not referred for MRI. An online referrals platform has been developed to streamline this process, initially deployed through a network of 60 centres registered in the UK. Funding Acknowledgement: Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): This work is supported by British Heart Foundation Innovations funding (HFHF_016).